Latest
13
Apr
AtaiBeckley's BPL-003 Shows Rapid, Durable TRD Response on SSRIs
Single intranasal dose of BPL-003 achieved 66.7% antidepressant response by Day 2 in treatment-resistant depression patients on stable SSRIs, with 83% durability at Day 85.
3 min read
01
Apr
Lilly, Novo, and the new terms of the oral obesity market
Orforglipron outperformed Rybelsus on every efficacy measure. The discontinuation rate is the number that matters now.
2 min read